Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: A systematic review and network meta-analysis

Annals of Internal Medicine

Volumn 162, Issue 1, 2015, Pages 46-54

  Bannuru, Raveendhara R ^a   Schmid, Christopher H ^b   Kent, David M ^a   Vaysbrot, Elizaveta E ^a   Wong, John B ^a   McAlindon, Timothy E ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CORTICOSTEROID; DICLOFENAC; HYALURONIC ACID; IBUPROFEN; NAPROXEN; PARACETAMOL; PLACEBO; ANALGESIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE; VISCOSUPPLEMENT;

ARTHRALGIA; CARDIOVASCULAR DISEASE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; JOINT STIFFNESS; KNEE FUNCTION; KNEE OSTEOARTHRITIS; KNEE PAIN; META ANALYSIS; PAIN; PLACEBO EFFECT; PRIORITY JOURNAL; REVIEW; SWELLING; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; COMPLICATION; INTRAARTICULAR DRUG ADMINISTRATION; OSTEOARTHRITIS, KNEE; TREATMENT OUTCOME;

ACETAMINOPHEN; ADRENAL CORTEX HORMONES; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; HUMANS; HYALURONIC ACID; IBUPROFEN; INJECTIONS, INTRA-ARTICULAR; NAPROXEN; OSTEOARTHRITIS, KNEE; PAIN; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME; VISCOSUPPLEMENTS;

EID: 84922377576     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-1231     Document Type: Review

References (39)

1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163-96. [PMID: 23245607] doi:10.1016/S0140-6736(12)61729-2
2. Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health. 1994;84:351-8. [PMID: 8129049]
3. Kosorok MR, Omenn GS, Diehr P, Koepsell TD, Patrick DL. Restricted activity days among older adults. Am J Public Health. 1992; 82:1263-7. [PMID: 1503169]
4. The incidence and prevalence database for procedures. Sunnyvale ,CA: Timely Data Resources. 1995:592-6.
5. White AG, Birnbaum HG, Janagap C, Buteau S, Schein J. Direct and indirect costs of pain therapy for osteoarthritis in an insured pop-ulation in the United States. J Occup Environ Med. 2008;50:998-1005. [PMID: 18784547] doi:10.1097/JOM.0b013e3181715111
6. McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med. 2013;10:e1001388. [PMID: 23424288] doi:10.1371/journal.pmed.1001388
7. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64:465-74. [PMID: 22563589]
8. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014; 22:363-88. [PMID: 24462672] doi:10.1016/j.joca.2014.01.003
9. Juhl C, Lund H, Roos EM, Zhang W, Christensen R. A hierarchy of patient-reported outcomes for meta-analysis of knee osteoarthritis trials: empirical evidence from a survey of high impact journals. Arthritis. 2012;2012:136245. [PMID: 22792458] doi:10.1155/2012/136245
10. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.10. The Cochrane Collaboration; 2011. Accessed at http://handbook.cochrane.org on 13 November 2014.
11. Cooper H, Hedges LV. The Handbook of Research Synthesis. New York: Russell Sage Foundation; 1994.
12. Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision making 1: introduction. Med Decis Making. 2013;33:597-606. [PMID: 23804506] doi:10.1177/0272989X13487604
13. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods. 2012;3:80-97. doi: 10.1002/jrsm.1037
14. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607-17. [PMID: 23104435] doi:10.1177/0272989X12458724
15. Franchini A, Dias S, Ades A, Jansen J, Welton N. Accounting for correlation in network meta-analysis with multi-arm trials. Research Synthesis Methods. 2012;3:142-60. doi: 10.1002/sim.6321
16. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med. 1996;15:2733-49. [PMID: 8981683]
17. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med. 1995; 14:2685-99. [PMID: 8619108]
18. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105-24. [PMID: 15449338]
19. Baker SG, Kramer BS. The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol. 2002;2:13. [PMID: 12429069]
20. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159:130-7. [PMID: 23856683] doi:10.7326/0003-4819-159-2-201307160-00008
21. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29: 932-44. [PMID: 20213715] doi:10.1002/sim.3767
22. Thorlund K, Walter SD, Johnston BC, Furukawa TA, Guyatt GH. Pooling health-related quality of life outcomes in meta-analysis - a tutorial and review of methods for enhancing interpretability. Research Synthesis Methods. 2011;2:188-203. doi: 10.1002/jrsm.46
23. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage. 2004;12:389-99. [PMID: 15094138]
24. Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 3: heterogeneity - subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making. 2013;33:618-40. [PMID: 23804507] doi:10.1177/0272989X13485157
25. Rutjes AW, Jüni P, da Costa BR, Trelle S, Nüesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med. 2012;157:180-91. [PMID: 22868835] doi:10.7326/0003-4819-157-3-201208070-00473
26. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee: evidence-based guideline. 2nd edition. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2013. Accessed at www.aaos.org/research/guidelines/treatmentofOsteo arthritisoftheKneeGuideline.pdf on 13 November 2014.
27. Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis - meta-analysis. Osteoarthritis Cartilage. 2011;19:611-9. [PMID: 21443958] doi:10.1016/j.joca.2010.09.014
28. Zhang RX, Ren K, Dubner R. Osteoarthritis pain mechanisms: basic studies in animal models. Osteoarthritis Cartilage. 2013;21: 1308-15. [PMID: 23973145] doi:10.1016/j.joca.2013.06.013
29. Gulen H, Ataoglu H, Haliloglu S, Isik K. Proinflammatory cytokines in temporomandibular joint synovial fluid before and after arthrocentesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:e1-4. [PMID: 19426899] doi:10.1016/j.tripleo.2009.02.006
30. Kirwan JR, Rankin E. Intra-articular therapy in osteoarthritis. Baillieres Clin Rheumatol. 1997;11:769-94. [PMID: 9429736]
31. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis. 2004;63:901-7. [PMID: 15020311]
32. Lee C, Hunsche E, Balshaw R, Kong SX, Schnitzer TJ. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis. Arthritis Rheum. 2005;53:510-8. [PMID: 16082648]
33. Stam W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. Open Rheumatol J. 2012;6:6-20. [PMID: 22582102] doi:10.2174/1874312901206010006
34. Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;43:593-9. [PMID: 24216297] doi:10.1016/j.semarthrit .2013.10.002
35. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006:CD005328. [PMID: 16625636]
36. Arroll B, Goodyear-Smith F. Corticosteroid injections for osteoarthritis of the knee: meta-analysis. BMJ. 2004;328:869. [PMID: 15039276]
37. Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:1704-11. [PMID: 19950318] doi:10.1002/art.24925
38. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006:CD005321. [PMID: 16625635]
39. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009;28: 1861-81. [PMID: 19399825] doi:10.1002/sim.3594